Risk-Reward Balanced at HGSI
May 24, 2011 at 15:02 PM EDT
We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $28.00. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US approval and launch of Benlysta earlier in the year for treating patients suffering from systemic lupus erythematosus (SLE) is a huge [...]
